Intravenous zoledronic acid in postmenopausal women with low bone mineral density

New England Journal of Medicine

Volumn 346, Issue 9, 2002, Pages 653-661

  Reid, Ian R ^a   Brown, Jacques P ^b   Burckhardt, Peter ^c   Horowitz, Zebulun ^d   Richardson, Peter ^d   Trechsel, Ulrich ^d   Widmer, Albert ^d   Devogelaer, Jean Pierre ^e   Kaufman, Jean Marc ^f   Jaeger, Philippe ^g   Body, Jean Jacques ^h   Brandi, Maria Luisa ^j   Broell, Johann ^k   Micco, Raffaele Di ^l   Genazzani, Andrea Riccardo ^m   Felsenberg, Dieter ⁿ   Happ, Joachim ^o   Hooper, Michael J ^p   Ittner, Jochen ^o   Leb, Georg ^q   Mallmin, Hans ^r   Murray, Timothy ^s   Ortolani, Sergio ^t   Rubinacci, Alessandro ^u   Sääf, Maria ^v   Samsioe, Goran ^w   Verbruggen, Leon ^x   Meunier, Pierre J ⁱ   more..

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITÉ LAVAL   (Canada)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF BERN   (Switzerland)

^h JULES BORDET INSTITUTE   (Belgium)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j CAREGGI UNIVERSITY HOSPITAL   (Italy)

^k KAISER FRANZ JOSEF HOSPITAL   (Austria)

^l MAGGIORE HOSPITAL   (Italy)

^m Ospedali Riuniti S Chiara   (Italy)

ⁿ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^o Strahlenklinik und Poliklinik ^*

^p Department of Microbiology and Infectious Diseases   (Australia)

^q UNIVERSITY HOSPITAL GRAZ   (Austria)

^r UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^s ST MICHAEL'S HOSPITAL   (Canada)

^t ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^u SAN RAFFAELE HOSPITAL   (Italy)

^v KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^w Kvinnokliniken   (Sweden)

^x UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PLACEBO; SODIUM CHLORIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; FEMALE; FEMUR NECK; FEVER; FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE REMODELING; COLLAGEN; COLLAGEN TYPE I; CREATININE; DIPHOSPHONATES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES;

EID: 0037186926     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa011807     Document Type: Article

References (27)

1. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
2. Effect of risedronate on the risk of hip fracture in elderly women
3. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause
4. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
5. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
6. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis
7. A dose-finding study of zoledronate in hypercalcemic cancer patients
8. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
9. Universal standardization of bone density measurements: A method with optimal properties for calibration among several instruments
10. On closed testing procedures with special reference to ordered analysis of variance
11. Effects of ibandronate i.v. bolus injection in healthy men and postmenopausal women
12. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
13. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: A 1-year, randomized, double-blind, placebo-controlled dose-finding study
14. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
15. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis
16. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
17. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
18. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
19. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
20. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
21. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial
22. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure
23. 3H-etidronate in rat and mouse bones
24. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts
25. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
26. Patient noncompliance with hormone replacement therapy: A nationwide estimate using a large prescription claims database
27. Compliance to bisphosphonates - A population-based study using a drug prescription database